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Abstract 
Introduction: Patients with symptomatic heart failure (HF) require additive therapies and have a poor 
prognosis. However, patient characteristics and clinical outcome between HF patients treated in the 
outpatient setting versus those who are hospitalized remain scarce.  
Methods: The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) 
included 2,516 patients with symptom and/or signs of HF: 1,694 as inpatients and 822 as outpatients.  
Results: Compared to ambulatory HF patients, inpatients had higher heart rate, urea, NT-proBNP, 
lower blood pressure, lower eGFR, sodium, potassium, HDL-cholesterol, had more often peripheral 
edema, diabetes, anemia, and were less often treated with beta-blockers and ACEi. Outpatients had a 
more frequent history of HF hospitalization and received more frequently beta-blockers and/or 
ACEi/ARBs up-titrated to target doses (p<0.001). Inpatients had higher rates of the primary outcome 
of death or HF hospitalization: incidence-rate per 100 person-years=33.4 (31.1-35.9) for inpatients vs. 
18.5 (16.4-21.0) for outpatients; adjusted HR (95%CI)=1.24 (1.07-1.43). Subdividing patients into 
low, intermediate and high-risk categories, the primary outcome event-rates were=14.3 (12.3-16.7), 
36.6 (32.2-41.5), and 71.3 (64.4-79.0) for inpatients vs. 8.4 (6.6-10.6), 29.8 (24.5-36.2), and 43.3 
(34.7-54.0) for outpatients, respectively. These findings were externally replicated. 
Conclusions: Marked differences were observed between inpatients and outpatients with HF. Overall, 
inpatients were sicker and had higher event-rates. However, a substantial proportion of outpatients 
had similar or higher event-rates compared to inpatients. These findings suggest that HF outpatients 
also have poor prognosis and may be the focus of future trials.  
 
Key-words: heart failure; trials; entry criteria; risk levels. 
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Introduction 
Heart failure (HF) is one of the diseases with the greatest healthcare expenditure1. The most important 
reason for this huge healthcare burden is recurrent unplanned HF hospitalization1, 2. Therefore, 
outpatient visits are becoming more frequently used to treat HF symptoms and optimize medical 
treatment, including alteration of diuretic doses and initiation/up-titration of neurohormonal 
antagonists, with an effective impact in reducing HF hospitalizations3.  
Patients hospitalized for HF have poorer prognosis compared with lower-risk, ambulatory 
patients4. However, retrospective and post-hoc data derived from clinical trials suggest that patients 
managed for HF symptoms in the outpatient setting may have similarly adverse prognosis compared 
to those managed as inpatients5, 6.  
The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) was a 
multicentre, multinational, European registry enrolling patients with HF and suboptimal medical 
treatment, either hospitalized or as outpatients7. It therefore allows the assessment of the clinical and 
prognostic differences of HF patients whether they have been hospitalized or not. Moreover, the 
identification of outpatients with a similar event risk as inpatients, would facilitate the selection of a 
wider population for future studies and randomized controlled trials (RCTs) without reducing the 
estimated event-rate and consequently not compromising the statistical power for assessing a potential 
treatment effect8.      
The aims of the present analysis are to: 1) compare the characteristics of patients enrolled as 
inpatients to those enrolled as outpatients; 2) to use the BIOSTAT-CHF risk score9 to assess the 
event-risk of both inpatients and outpatients; and 3) to compare inpatients and outpatients according 
to the individual-patients` risk.  
 
Methods 
Patient population and risk model development 
BIOSTAT-CHF is a European project that enrolled 2,516 HF patients from 69 centres in 11 
European countries to determine profiles of patients with HF that do not respond to recommended 
therapies, despite anticipated up-titration. The design and first results of the study and patients have 
been described elsewhere7. In brief, patients were aged ≥18 years with signs and symptoms of HF, 
confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or a BNP and/or NT-proBNP 
plasma levels >400 pg/mL and/or >2000 pg/mL, respectively. Patients needed to be treated with either 
oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. Patients should not 
have been previously treated with evidence-based therapies (ACEi/ARBs and beta-blockers) or were 
receiving <50% of the target doses of at least one of these drugs at the time of inclusion10, 11. The first 
three months of treatment were considered to be the optimization phase after which a stabilization 
phase of 6 months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB 
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and/or β-blocker was performed according to the routine clinical practice of the treating physicians, 
who were encouraged to follow the ESC guidelines at the time of treatment10, 11. Patients reaching at 
least 50% of the recommended dose of ACEi/ARB and/or β-blocker were considered successfully up-
titrated. 
The recruitment period was 24 months, starting from December 2010. The last patient was 
included on December 15, 2012.  
The median follow-up was 21 months.  
The primary outcome was a composite of HF hospitalization and all-cause death. The 
components of the primary outcome were also assessed separately as exploratory outcomes. The 
adjudication of HF hospitalization was performed by the treating physician. After the trial has ended 
all medical reports of the deadly event were read and adjudicated by an independent committee of 
cardiologists and cardiovascular death was also possible to ascertain.   
Ethics Board approval was obtained and all participants signed written informed consent 
before entering the study.  
The BIOSTAT-CHF risk models have been previously developed and validated9.  
Validation cohort 
The findings presented herein were also externally validated. The BIOSTAT-CHF validation cohort 
was designed as a multicentre, prospective, observational study. The study population consisted of 
1,738 patients from six centres in Scotland, UK. The recruitment period started in October 2010 and 
was completed in April 2014. Median follow-up was 21 months. Patients from the validation cohort 
were aged >18 years with a HF diagnosis based on echocardiographic evidence of left ventricular 
(LV) dysfunction or a previous documented admission with HF treated with furosemide ≥20 mg/day 
or equivalent, not previously treated or receiving ≤50% of target doses of ACE inhibitors/ARBs 
and/or beta-blockers according to the 2008 European Society of Cardiology guidelines. Patients could 
be enrolled as inpatients or from outpatient clinics7.  
Statistical analysis 
Population description and comparison of outpatients vs. inpatients was performed using t-test, Mann-
Whitney or chi-square test, as appropriate.  
Cox proportional hazard regression models were used to model long-term event rate of the 
variables included in the previously published BIOSTAT-CHF risk models9. Proportional hazard 
assumption was verified graphically using "log-log" plots. Log-linearity was checked by testing the 
functional forms of the covariable by the Kolmogorov-type supremum test and by visual inspection 
by plotting the beta estimates versus the mean across quintiles. Missing predictor values were imputed 
using multichain Monte Carlo methods with Gibbs sampling9. We imputed missing data five times, 
performed the analysis over all five imputations and averaged results using Rubin’s rules12.  
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An integer-point risk score was created to assess each patients` individual risk and allow the 
comparison of outpatients to inpatients according to their probability of future events. In order to 
create a simple integer risk score, continuous variables included in the chosen model, were 
categorized into either two or three groups using a combination of established clinical cut-points and 
graphical examination of rates across quintiles. To simplify the risk score, integer points were 
assigned to each prognostic factor based upon the log-hazard ratio estimates. The total risk score for 
each patient was calculated by summing the points across all chosen prognostic variables. From the 
overall distribution of the risk score we formed three categories (tertiles) of risk, containing 
approximately equal number of events. Within each risk category we calculated the number of events, 
person-years at risk, and the overall event rate. Kaplan–Meier plots were drawn showing the 
cumulative incidence curves of outpatients vs. inpatients and risk category. 
The covariates used for adjustment when comparing the hazard ratio of inpatients vs. 
outpatients were chosen from demographic (age and gender), clinical (previous HF hospitalization, 
use of beta-blockers and systolic blood pressure), and laboratory (NT-proBNP, blood urea nitrogen, 
hemoglobin, HDL-cholesterol, estimated glomerular filtration rate [eGFR] by the CKD-EPI formula13, 
14, and sodium). All these parameters were previously found to be independently associated with the 
outcomes in the BIOSTAT-CHF cohort and were the parameters used to build the risk models 
depicted herein (URL: https://biostat-chf.shinyapps.io/calc/)9. The BIOSTAT-CHF risk models were 
externally validated and showed good internal calibration and consistency across levels of risk and 
geographical regions9.   
Hospitalization for HF was analyzed using a competing risk model (accounting for death as 
competing risk), as described by Fine and Gray15.  
All the analyses were performed using STATA (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). A p-value <0.05 was considered as statistically 
significant. 
 
Results 
Characteristics of the study population 
A total of 2,516 patients were analyzed, 822 as outpatients and 1,694 as inpatients. The mean age was 
≈68 years and >70% were male. Compared to HF outpatients, in-hospital enrolled patients had higher 
heart rate, urea, NT-pro BNP, lower blood pressure, lower eGFR, sodium, potassium, HDL 
cholesterol, had more often peripheral edema, rales, orthopnea, elevated jugular venous pressure, 
NYHA class III or IV, new-onset HF admission, diabetes, anemia, and were less often treated with 
beta-blockers and ACE inhibitors (Table 1). Age and LVEF was similar between groups and 
outpatients had been more often hospitalized for HF in the previous year and had beta-blockers and/or 
ACEi/ARBs up-titrated more often (Table 1).  
Outcome associations 
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Compared to HF outpatients, inpatients had higher rates of primary outcome events: adjusted HR 
(95%CI) =1.24 (1.07-1.43) and HF hospitalization events =1.38 (1.14-1.66), but not mortality =1.11 
(0.92-1.34). Table 2. The Kaplan-Meier curves for the primary outcomes are shown in Figure 1. 
 Outpatients had 247 (30%) primary outcome events, 152 (18%) HF hospitalization events, 
and 155 (19%) deaths, with corresponding incidence rates per 100 person-years =18.5 (16.4-21.0), 
11.4 (9.7-13.3), and 10.4 (9.0-12.3). Inpatients had 767 (45%) primary outcome events, 456 (27%) HF 
hospitalization events, and 502 (27%) deaths, with corresponding incidence rates per 100 person-
years =33.4 (31.1-35.9), 19.8 (18.1-21.7), and 18.1 (16.6-19.8).  
Risk model 
The integer score derived from the BIOSTAT-CHF risk model provided a maximum of 15 points 
(Table 3). Dividing the risk score in tertiles we classified patients as: from 0 to 4 points =low risk 
(n=1,058); 5 to 7 points =intermediate risk (n=746); 8 to 15 points =high risk (n=712).  
Incidence rates by risk categories 
The primary outcome incidence rates per 100 person-years according to the risk categories were: low-
risk =11.8 (10.4-13.4), intermediate risk =34.3 (30.8-38.1), and high risk =64.0 (58.3-70.2). Table 4. 
The distribution of patients and events by categories of risk is depicted in Table 4. For 
outpatients, 437 (53%) were in the low risk, 233 (28%) in the intermediate risk, and 152 (19%) in the 
high-risk category. The corresponding n. (%) of primary outcome events by category of risk was 68 
(16%), 100 (43%), and 79 (52%), respectively. For inpatients, 621 (37%) were in the low risk, 513 
(30%) in the intermediate risk, and 560 (33%) in the high-risk category. The corresponding n. (%) of 
primary outcome events by category of risk was 162 (26%), 238 (46%), and 367 (66%), respectively.    
Outpatients had primary outcome incidence rates of 8.4 (6.6-10.6), 29.8 (24.5-36.2), and 43.3 
(34.7-54.0) for low, intermediate, and high-risk categories, respectively. Inpatients had primary 
outcome incidence rates of 14.3 (12.3-16.7), 36.6 (32.2-41.5), and 71.3 (64.4-79.0) for low, 
intermediate, and high-risk categories, respectively. Table 4 & Figure 2. Incidence rates for the 
individual components of the primary outcome are depicted in Table 4. Outpatients in the 
intermediate and high-risk categories had similar event rates compared to inpatients overall. Figure 3. 
External validation 
Similar findings were found in the validation cohort. Outpatients in the intermediate and high-risk 
categories had similar primary outcome (HF hospitalization or death) event rates compared low-risk 
and intermediate-risk categories inpatients, respectively. Supplemental Material Tables 1 to 3.  
Cardiovascular mortality 
Cardiovascular mortality (CVM) represented 67% (441/657) of all deaths. The associations for CVM 
were similar to those above described for all-cause mortality. Supplemental Tables 4 & 5. The 
associations for the outcome of CVM or HF hospitalization were similar to those above described for 
the primary outcome (data not shown). 
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Discussion 
The present study shows that HF inpatients were different from outpatients. Inpatients had more co-
morbidities and higher overall event rates. However, outpatients classified as having intermediate 
and/or high risk had similar event-rates compared to inpatients overall population. Nevertheless, it 
should be noted that more than half (53%) of outpatients were classified as “low-risk” with 
corresponding low event rates that may not be suitable for a HF trial.  In addition, the outcome 
difference between outpatients and inpatients was mainly observed due to differences in 
hospitalization rates. These data demonstrate that HF outpatients are patients at high risk of major 
events and should also be considered to be included in trials, as they may present similar risk to 
inpatients. Moreover, symptomatic HF in the outpatient setting could also be considered for 
incorporation in the composite primary outcome of contemporary trials, providing more detailed 
events (e.g., IV diuretic administration and/or need for increasing oral diuretics) are available for 
adjudication. Moreover, the simple integer score generated in the present analysis provides a “ready-
to-use” tool for enhancing patients` risk in future HF studies, particularly for outpatient selection – 
selecting intermediate to high-risk outpatients based on our risk score allows the selection of a HF 
population with similar event-rates compared to hospitalized patients. These findings were replicated 
externally. To the best of our knowledge this is the first study to compare outpatients vs. inpatients by 
levels of individual risk.  
Many patients with symptomatic HF have a gradual evolution of congestive signs and 
symptoms, offering a potential window in which effective therapy may abort continued worsening 
and prevent the need for hospitalization16. Additionally, the so-called “home time” (i.e., time alive and 
out of a health care institution) is an important patient-centered outcome17. Hence, more focus should 
be provided to HF outpatients (e.g., in “IV diuretic clinics”) as interventions in this setting may avoid 
downstream hospitalizations16. Outpatients may also be more suitable for medication up-titration as 
they may be less symptomatic and present less co-morbid conditions16. This assumption was 
corroborated in the present analysis in which HF outpatients had less co-morbidities and were more 
often up-titrated to target doses for both beta-blockers and ACEi/ARBs. Outpatients were admitted 
less frequently as “new-onset” HF. This is likely due to the fact that only patients with known HF 
history are referenced for HF clinics. It should be noted that patients with “new-onset” HF likely have 
improved survival compared to patients with chronic HF diagnoses18, however the higher proportion 
of “new-onset” HF patients in the inpatient group did not reduce the overall risk of this population nor 
this variable was retained in the “best” risk model. 
The event-rates observed in the BIOSTAT-CHF study (including the validation cohort) were 
superior to those observed in contemporary chronic HF RCTs but overlapped those observed in acute 
HF trials and registries19-22. For example, the event-rates per 100 person-years observed in the 
PARADIGM-HF (Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure) trial19 for the 
primary outcome of HF hospitalization or cardiovascular death varied from 9 to 15 events per 100 
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person-years (depending on the geographic region23) which were lower than those that we observed in 
BIOSTAT-HF for outpatients (16 to 21 events per 100 person-years) and nearly half of the event-rates 
observed for inpatients (31 to 36 events per 100 person-years). However, we must consider the 
different inclusion criteria of the two studies, chronic stable HF in PARADIGM-HF versus 
symptomatic and under-treated HF in BIOSTAT-CHF, and that cardiovascular, rather than all-cause, 
mortality was assessed as a component of the primary endpoint in PARADIGM-HF. Comparable 
event-rates were only observed in the lower risk category of the BIOSTAT-CHF (10 to 13 events per 
100 person-years). The event rates observed in the Eplerenone in Patients with Systolic Heart Failure 
and Mild Symptoms (EMPHASIS-HF) trial24 were also much lower compared to those observed in 
the BIOSTAT-CHF, with only the high-risk patients in the placebo group in the EMPHASIS-HF 
having similar event rates (for the primary outcome of cardiovascular death or HF hospitalization) to 
those observed in inpatients from BIOSTAT (~39 per 100 person-years)25. These findings suggest that 
patients with HF enrolled in the BIOSTAT-CHF were more severe than those enrolled in 
contemporary chronic HF trials. However, HF symptoms were not needed at the time of enrolment in 
these trials, and patients were younger, less symptomatic and with less co-morbidities than those 
enrolled in the BIOSTAT-CHF19, 24. The proportion of events observed in the EVEREST (Effects of 
Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure) trial in a median follow-up of 
10 months, overlapped that observed in BIOSTAT-CHF. The EVEREST trial (tolvaptan vs. placebo) 
was “neutral”, and 41% of patients experienced cardiovascular death or HF hospitalization and 26% 
died from any cause21. This proportion of events is similar to that observed in the intermediate risk of 
the BIOSTAT-CHF population, both for inpatients and outpatients. In the ASTRONAUT (Effect of 
Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized 
for Heart Failure) trial, during a median follow-up of 11 months there were no statistically significant 
differences between aliskiren and placebo in events, and 25% of patients died from cardiovascular 
causes or were hospitalized for HF and 18% died from any cause22. The proportion of events in the 
ASTRONAUT trial are more similar to those observed in the low risk category for inpatients and 
intermediate risk for outpatients. Regarding “acute” HF registries, the event-rates observed in patients 
with decompensated HF in the ESC-HF-LT (European Society of Cardiology Heart Failure Long-
Term Registry) overlapped those observed herein. These findings suggest that the BIOSTAT-CHF 
population resembles much more an “acute” rather than “chronic” HF population20. These findings 
suggest that outpatients with HF signs and symptoms plus elevated NPs are also a “high-risk” 
population6.  
As stated in the protocol, dose up-titration to target doses of evidence-based therapies was 
always recommended. However, only 53% and 40% of the patients reached ≥50% of the target doses 
of ACEi/ARB and BB, respectively. Not reaching ≥50% of the target dose of ACEi/ARB or BB was 
associated with worse outcomes (compared with patients who reached >50% of the target dose)26. 
MRAs remained extensively underused throughout the study27. 
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 In the present analysis we also found that the higher event-rates observed in inpatients was 
mostly due to the burden of HF hospitalization (with similar rates for outpatients in intermediate/high 
risk categories). Hence, reducing HF symptoms and the burden of hospitalizations is an important 
target of any HF intervention or therapy19, 24, 28. However, this also shows that HF hospitalization and 
mortality may be dissociated in the clinical course of the HF patients and that the variables related 
with HF hospitalization may differ from those related with mortality29. In the present study 
cardiovascular mortality represented 67% of all deaths, and the associations described for all-cause 
death are similar to those observed for cardiovascular mortality.   
Risk enhancement strategies are used in HF trials and registries in order to increase the 
specificity for the presence of HF and the odds of subsequent events necessary to ascertain prognostic 
associations and/or treatment effect with adequate power and precision. Hence, many studies include 
only patients hospitalized for HF as these have higher risk for subsequent events19, 30. Moreover, NP 
thresholds are increasingly used with both purposes of increasing HF specificity and risk19, 28, 29. In the 
present study we demonstrate that a high proportion of outpatients have similar risk as inpatients. Due 
to the high event rate in these outpatients with HF, they might also be a target for better future 
therapies. In this regard, the present study provides a useful tool for “risk-enhancement” in futures HF 
studies and trials.  
 
Limitations 
Several limitations should be acknowledged in this analysis. First, this is a post-hoc analysis of a 
prospective non-randomized observational study, therefore all limitations inherent to such analysis are 
applied herein, including the inability to infer causality. Second, the data from the BIOSTAT-CHF 
come from European centres only and may not be representative of HF patients in other world 
regions. Third, all patients enrolled in the BIOSTAT-CHF had severe symptoms and high NP levels, 
hence these findings cannot be generalized to less symptomatic HF patients. Fourth, the proportion of 
patients (especially outpatients) with LVEF >40% was very low (4 to 12 %) and these results cannot 
be generalised to patients with “mid-range or preserved” ejection fraction. Lastly, IV diuretic use was 
not registered in the outpatient setting, hence we cannot ascertain how many of these patients could be 
considered as “true” worsening HF.   
 
Conclusions 
Marked differences were observed between inpatients and outpatients with HF. Overall, inpatients 
were sicker and had higher event-rates. However, a substantial proportion of outpatients had similar 
or higher event-rates compared to inpatients. These findings suggest that HF outpatients, usually not 
enrolled in HF trials nor considered as endpoints, also have poor prognosis and may be the focus of 
future trials. 
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Table 1. Baseline characteristics of the study population 
Patients` characteristics Outpatient Inpatient P-value 
n=2,516 n=822 n=1,694 
Age, yr 68.1 ± 11.3 68.5 ± 12.3 0.45 
Male, n (%) 629 (77 %) 1217 (72 %) 0.013 
BMI, Kg/m2 27.8 ± 5.1 27.9 ± 5.7 0.62 
Heart rate, bpm 75.3 ± 16.0 85.7 ± 22.8 <0.001 
SBP, mmHg 127.3 ± 19.9 123.5 ± 22.7 <0.001 
Ischemic HF, n (%) 397 (48 %) 706 (42 %) 0.002 
HFH in the last year, n (%) 332 (40 %) 462 (27 %) <0.001 
Peripheral edema, n (%) 298 (36 %) 958 (57 %) <0.001 
Pulmonary congestion/Rales, n (%) 208 (26 %) 1,083 (65%) <0.001 
Elevated JVP, n (%) 119 (22 %) 435 (36 %) <0.001 
Orthopnea, n (%) 134 (16 %) 745 (44 %) <0.001 
NYHA class III or IV, n (%) 378 (46 %) 1,144 (70 %) <0.001 
LVEF, % 30.5 ± 8.6 31.3 ± 11.5 0.063 
LVEF >40%, n (%) 33 (4 %) 202 (12 %) <0.001 
Worsening HF admission, n (%) 422 (51 %) 950 (56 %)  
New-onset HF admission, n (%) 78 (10 %) 624 (37 %) <0.001 
Non-documented/Other, n (%) 322 (39 %) 120 (7 %)  
Atrial fibrillation, n (%) 359 (44 %) 784 (46 %) 0.22 
Diabetes, n (%) 236 (29 %) 583 (34 %) 0.004 
COPD, n (%) 132 (16 %) 304 (18 %) 0.24 
Anemia, n (%) 182 (22 %) 681 (40 %) <0.001 
Urea, mmol/L 13.0 ± 6.2 15.8 ± 12.2 <0.001 
eGFR, ml/min/1.73m2 67.5 ± 22.8 59.9 ± 23.0 <0.001 
Sodium, mmol/L 139.7 ± 3.1 138.8 ± 4.1 <0.001 
Potassium, mmol/L 4.4 ± 0.5 4.2 ± 0.6 <0.001 
HDL, mmol/L 1.2 ± 0.4 1.1 ± 0.4 <0.001 
NT-pro BNP, pg/mL 2,904 (1,490-5,078) 5,000 (2,689-9,577) <0.001 
No beta-blocker, n (%) 85 (10 %) 338 (20 %) <0.001 
No ACEi/ARB 172 (21 %) 524 (31 %) <0.001 
No MRA, n (%) 396 (48 %) 781 (46 %) 0.33 
Up-titration* (n=2139) n=769 n=1370  
ACEi/ARB, n (%) 488 (63%) 682 (50%) <0.001 
Beta-blocker, n (%) 337 (44 %) 440 (32 %) <0.001 
ACEi/ARB or beta-blocker, n (%) 586 (76 %) 859 (63%) <0.001 
Legend: BMI, body mass index; SBP, systolic blood pressure; JVP, jugular venous pressure; HFH, 
heart failure hospitalization; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular 
ejection fraction; eGFR, estimated glomerular filtration rate; HDH, high-density lipoprotein 
cholesterol; NT-pro BNP, N-terminal pro brain natriuretic peptide; ACEi/ARB, angiotensin 
converting enzyme inhibitor/angiotensin receptor blocker; MRA, mineralocorticoid receptor 
antagonist. 
*Up-titration period occurred during the first 3 months after inclusion in the study, hence patients who 
died or that were lost to follow-up were excluded from the up-titration analysis (see methods section). 
 
 
 
 
 
 
Table 2. Hazard ratios, incidence rates and respective 95% confidence intervals for the study 
outcomes 
Inpatient vs. Outpatient Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
HFH or death 1.74 (1.51-2.01) <0.001 1.24 (1.07-1.43) 0.005 
Death 1.72 (1.43-2.06) <0.001 1.11 (0.92-1.34) 0.26 
HFH 1.67 (1.39-2.01) <0.001 1.38 (1.14-1.66) 0.001 
*Adjusted on the BIOSTAT-CHF risk model including age, heart failure hospitalization in the 
previous year, peripheral edema, systolic blood pressure, estimated glomerular filtration rate, urea, 
NT-pro BNP, hemoglobin, HDL cholesterol, sodium, and beta-blocker use.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Multivariate risk model 
Final model HR (95%CI) Coef. P-value Integer 
Age ≤65 yr Reference - - - 
Age 65 to 75 1.09 (0.91-1.30) 0.09 0.35 - 
Age >75 1.34 (1.12-1.60) 0.29 0.002 +1 
HFH in the last year 1.44 (1.25-1.65) 0.36 <0.001 +1 
Peripheral edema 1.31 (1.11-1.53) 0.26 0.001 +1 
SBP ≤110 mmHg 1.28 (1.11-1.47) 0.25 0.001 +1 
eGFR >60 ml/min/1.73m2 Reference - - - 
eGFR 45 to 60 1.19 (0.99-1.42) 0.17 0.058 - 
eGFR <45 1.37 (1.14-1.65) 0.32 0.001 +1 
Urea <8 mmol/L Reference - - - 
Urea 8 to 16  1.26 (1.04-1.54) 0.23 0.019 +1 
Urea >16 1.50 (1.20-1.86) 0.40 <0.001 +1 
NT-pro BNP 2000-3000 pg/mL Reference - - - 
NT-pro BNP 3000-7000 2.04 (1.65-2.54) 0.71 <0.001 +2 
NT-pro BNP >7000 2.86 (2.26-3.62) 1.05 <0.001 +3 
Anemia  1.32 (1.15-1.52) 0.28 <0.001 +1 
HDL <1 mmol/L 1.20 (1.03-1.40) 0.19 0.017 +1 
Sodium <135 mmol/L 1.16 (0.97-1.38) 0.15 0.10 - 
No beta-blocker at baseline 1.37 (1.16-1.61) 0.31 <0.001 +1 
The presented model was built for the primary outcome of heart failure hospitalization or death*. 
C-index=0.70 
Legend: HFH, hospitalization for heart failure; SBP, systolic blood pressure; eGFR, estimated 
glomerular filtration rate; NT-pro BNP, N-terminal pro brain natriuretic peptide; HDL, high-density 
cholesterol. 
*The best risk model incorporates the same variables for all the studied outcomes (URL: 
https://biostat-chf.shinyapps.io/calc/). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Event proportion and incidence rates per 100-person years of outpatients and inpatients by categories of the risk score and study outcomes 
HFH or death Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 1,058/230 (22 %) 11.8 (10.4-13.4) 437/68 (16 %) 8.4 (6.6-10.6) 621/162 (26 %) 14.3 (12.3-16.7) 
Intermediate (5-6) 746/338 (45 %) 34.3 (30.8-38.1) 233/100 (43 %) 29.8 (24.5-36.2) 513/238 (46 %) 36.6 (32.2-41.5) 
High (7-15) 712/446 (63 %) 64.0 (58.3-70.2) 152/79 (52 %) 43.3 (34.7-54.0) 560/367 (66 %) 71.3 (64.4-79.0) 
 
Death Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 1,058/131 (12 %) 6.3 (5.3-7.4) 437/44 (10 %) 5.2 (3.8-7.0) 621/87 (14 %) 7.0 (5.7-8.6) 
Intermediate (5-6) 746/200 (27 %) 16.3 (14.2-18.7) 233/59 (25 %) 14.6 (11.3-18.9) 513/141 (27 %) 17.2 (14.5-20.2) 
High (7-15) 712/326 (46 %) 35.1 (31.5-39.1) 152/52 (34 %) 23.2 (17.7-30.4) 560/274 (49 %) 38.9 (34.5-43.7) 
 
HFH Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 1,058/142 (13 %) 7.3 (6.2-8.6) 437/39 (9 %) 4.8 (3.5-6.6) 621/103 (17 %) 9.1 (7.5-11.1) 
Intermediate (5-6) 746/213 (29 %) 21.5 (18.8-24.6) 233/63 (27 %) 18.7 (14.6-23.9) 513/150 (29 %) 23.0 (19.6-27.0) 
High (7-15) 712/253 (36 %) 36.1 (31.9-40.8) 152/50 (33 %) 27.2 (20.6-35.9) 560/203 (36 %) 39.2 (34.1-45.0) 
Legend: HFH, hospitalization for heart failure; n., number; pts, patients. 
 
Figure 1. Kaplan-Meier failure estimates for the primary outcome of heart failure hospitalization or 
death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Incidence rates per 100 person
or death by tertiles of risk score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-years for the primary outcome of heart failure hospitalization 
 
Figure 3. Incidence rates per 100 person
or death with comparison of outpatients` risk levels with inpatients overall risk
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Supplemental Table 1. Validation cohort: multivariate risk model 
Final model HR (95%CI) Coef. P-value Integer 
Age ≤65 yr Reference - - - 
Age 65 to 75 1.12 (0.89-1.40) 0.11 0.32 - 
Age >75 1.30 (1.05-1.62) 0.27 0.018 +1 
HFH in the last year 1.39 (1.20-1.62) 0.33 <0.001 +1 
Peripheral edema 1.39 (1.19-1.63) 0.33 <0.001 +1 
SBP ≤110 mmHg 1.23 (1.06-1.44) 0.21 0.008 +1 
eGFR >60 ml/min/1.73m2 Reference - - - 
eGFR 45 to 60 1.10 (0.88-1.38) 0.09 0.38 - 
eGFR <45 1.04 (0.86-1.26) 0.04 0.66 +1 
Urea <8 mmol/L Reference - - - 
Urea 8 to 16  1.24 (1.04-1.49) 0.22 0.019 +1 
Urea >16 1.44 (1.09-1.91) 0.37 0.011 +1 
NT-pro BNP 2000-3000 pg/mL Reference - - - 
NT-pro BNP 3000-7000 1.82 (1.53-2.18) 0.60 <0.001 +2 
NT-pro BNP >7000 2.07 (1.68-2.56) 0.73 <0.001 +3 
Anemia  1.30 (1.12-1.52) 0.27 0.001 +1 
HDL <1 mmol/L 1.08 (0.94-1.25) 0.08 0.28 +1 
Sodium <135 mmol/L 1.14 (0.90-1.43) 0.13 0.27 - 
No beta-blocker at baseline 1.00 (0.86-1.18) 0.004 0.97 +1 
Legend: HFH, hospitalization for heart failure; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; NT-pro BNP, N-terminal 
pro brain natriuretic peptide; HDL, high-density cholesterol. 
*The best risk model incorporates the same variables for all the studied outcomes (URL: https://biostat-chf.shinyapps.io/calc/). 
 
  
 Supplemental Table 2. Validation cohort: hazard ratios, incidence rates and respective 95% confidence intervals for the study outcomes 
Inpatient vs. Outpatient Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
HFH or death 2.18 (1.89-2.51) <0.001 1.36 (1.16-1.58) <0.001 
Death 2.33 (1.97-2.78) <0.001 2.14 (1.80-2.55) <0.001 
HFH 1.76 (1.48-2.09) <0.001 1.30 (1.08-1.57) 0.005 
*Adjusted on the BIOSTAT-CHF risk model including age, heart failure hospitalization in the previous year, peripheral edema, systolic blood 
pressure, estimated glomerular filtration rate, urea, NT-pro BNP, hemoglobin, HDL cholesterol, sodium, and beta-blocker use.   
C-statistic for risk score mortality/HF hospitalization =0.66; mortality only =0.71; HF hospitalization only 0.61  
Supplemental Table 3. Validation cohort: event proportion and incidence rates per 100-person years of outpatients and inpatients by 
categories of the risk score and study outcomes 
HFH or death Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 848/285 (34 %) 13.4 (11.9-15.0) 522/156 (27 %) 10.5 (9.0-12.3) 326/129 (35 %) 19.9 (16.8-23.7) 
Intermediate (4-6) 446/259 (58 %) 31.4 (27.8-35.5) 201/107 (50 %) 23.2 (19.2-28.0) 245/152 (57 %) 41.9 (35.8-49.2) 
High (7-12) 384/267 (70 %) 61.9 (54.9-69.7) 57/36 (58 %) 37.9 (27.4-52.6) 327/231 (70 %) 68.6 (60.3-78.1) 
 
Death Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 848/160 (19 %) 6.1 (5.2-7.1) 522/83 (16 %) 4.8 (3.9-6.0) 326/77 (24 %) 8.7 (6.9-10.8) 
Intermediate (4-6) 446/170 (38 %) 14.3 (12.3-16.6) 201/69 (34 %) 11.5 (9.1-14.6) 245/101 (41 %) 17.0 (14.0-20.7) 
High (7-12) 384/235 (61 %) 33.3 (29.3-37.9) 57/32 (56 %) 25.5 (18.1-36.1) 327/203 (62 %) 35.0 (30.5-40.2) 
 
HFH Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 848/197 (23 %) 8.5 (7.4-9.7) 522/107 (20 %) 6.8 (5.6-8.2) 326/90 (28 %) 12.2 (9.9-14.9) 
Intermediate (4-6) 446/175 (39 %) 17.3 (15.0-20.1) 201/76 (38 %) 14.4 (11.5-18.0) 245/99 (40 %) 20.6 (16.9-25.1) 
High (7-12) 384/169 (44 %) 24.3 (20.9-28.2) 57/20 (35 %) 15.2 (9.8-23.6) 327/149 (61 %) 26.4 (22.5-31.0) 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4. Derivation cohort: hazard ratios, incidence rates and respective 95% confidence intervals for cardiovascular death 
Inpatient vs. Outpatient Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
Cardiovascular Death 1.81 (1.45-2.26) <0.001 1.16 (0.92-1.47) 0.20 
*Adjusted on the BIOSTAT-CHF risk model including age, heart failure hospitalization in the previous year, peripheral edema, systolic blood 
pressure, estimated glomerular filtration rate, urea, NT-pro BNP, hemoglobin, HDL cholesterol, sodium, and beta-blocker use.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 5. Derivation cohort: cardiovascular death event proportion and incidence rates per 100-person years of outpatients and 
inpatients by categories of the risk score  
Cardiovascular death Total  Outpatients Inpatients 
Risk category n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate n. pts/events (%) Incidence-rate 
Low (0-4) 1,058/88 (8 %) 4.2 (3.4-5.2) 437/29 (7 %) 3.4 (2.4-4.9) 621/59 (10 %) 4.7 (3.7-6.1) 
Intermediate (5-6) 746/131 (18 %) 10.7 (9.0-12.7) 233/41 (18 %) 10.2 (7.5-13.8) 513/90 (18 %) 11.0 (8.9-13.5) 
High (7-15) 712/222 (31 %) 23.9 (20.9-27.3) 152/30 (20 %) 13.4 (9.4-19.2) 560/192 (34 %) 27.3 (23.7-31.4) 
 
